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Abstract: The discovery of effective cancer treatments is a key goal for pharmaceutical companies. However, the current costs of bring-
ing a cancer drug to the market in the USA is now estimated at $1 billion per FDA approved drug, with many months of research at the 
bench and costly clinical trials. A growing number of papers highlight the use of data mining tools to determine associations between 
drugs, genes or protein targets, and possible mechanism of actions or therapeutic efficacy which could be harnessed to provide informa-
tion that can refine or direct new clinical cancer studies and lower costs. This report reviews the paper by R.J. Epstein, which illustrates 
the potential of text mining using Boolean parameters in cancer drug discovery, and other studies which use alternative data mining 
approaches to aid cancer research.
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commentary
The  discovery  of  effective  treatments  for  cancer 
represents a key goal for pharmaceutical companies 
who wish to identify drugs that can prolong survival 
time  and  even  reverse  cancers,  while  having  an 
acceptable  toxicity  profile.  However,  the  average 
cost of bringing a drug to the commercial market 
in the USA is now estimated at $1 billion per FDA 
approved drug, and many factors have compounded 
the expense of these developments such that cancer 
drug  discovery  is  now  both  extremely  slow  and 
costly even for a potential blockbuster. Among the 
many factors contributing to the cost are the high 
price  of  clinical  trial  organisation  and  the  bench 
research hours required to validate the efficacies and 
toxicities associated with a drug despite the use of 
time saving technologies such as high throughput 
screening to determine efficacies and genomic anal-
yses of drug effects. A growing number of papers 
highlight the use of data mining tools to determine 
associations between drugs, genes or protein targets, 
and  possible  mechanism  of  actions  or  therapeu-
tic  efficacy  which  could  be  harnessed  to  provide 
information  that  can  refine  or  direct  new  clinical 
cancer studies.
One common method of data mining is referred to 
as text mining. Richard Epstein1 provides a number of 
examples of how text mining using Boolean terms can 
be used to determine associations between a cancer 
type or drug and the symptoms or efficacies observed. 
For example he describes how phenotypes and envi-
ronmental  factors  associated  with  either  squamous 
cell carcinoma or adenocarcinoma (e.g. smoking and 
lymph node metastasis for squamous cell carcinoma 
vs. hormone and liver metastasis for adenocarcinoma) 
can be deciphered. Mechanistic associations of dif-
ferent drugs such as tyrosine kinase inhibitors and 
metalloprotease  inhibitors  can  also  be  calculated: 
Growth or replication is more strongly associated with 
tyrosine kinase inhibitors and invasion and metastasis 
inhibition is more strongly associated with metallo-
protease inhibitors.
Epstein also provides examples of how text mining 
can determine associations between types of cancers 
and a particular gene for example, AKT.2 The gene for 
AKT encodes a retroviral protein which is a pivotal 
cell signalling protein which when activated leads to 
inhibition of cellular apoptosis and activation of its 
downstream target (mammalian target of rapamycin 
(mTOR)), which increases mRNA translation through 
combination with its protein RAPTOR (regulatory-
associated protein of mTOR). By text mining associa-
tions, AKT is associated with a number of cancers of 
which the most prominent is prostate cancer. When the 
association is then compared with cancers in which 
the mTOR inhibitor temsirolimus has been used, pros-
tate cancer also gives the strongest correlation as the 
disease in which this drug has been most commonly 
used. Therefore, text mining can detect correlations 
between specific cancers and their associated gene 
defects and the drugs that are used for that cancer. 
A number of papers have shown how text mining has 
contributed greatly to identifying critical genes and 
drugs in a number of cancers. For example Pospisil 
et al have used a combined textual-structural mining 
approach to identify potential enzyme targets in the 
extracellular space of cancerous cells for six com-
mon, lethal human tumors, by searching databases 
such as PubMed abstracts, NCBI Entrez, UniProt, 
(a  universal  gene/protein  database)  and  Interpro, 
a conserved protein domains database. By using key-
word and gene ontology terms and by clustering these 
terms to specific cell locations, a list of cancer-related 
hydrolases  for  each  tumor  type  have  been  identi-
fied  as  therapeutic  targets  including  prostatic  acid 
phosphatase (ACPP also known as PAP), prostate-
specific antigen (PSA) and sulfatase 1 (SULF1).3,4 
Another study by Turk et al have used text mining of 
National Cancer Institute’s DTP drug repository to 
search for compounds showing increased toxicity in 
MDR cells and discovered 22 compounds with MDR 
specific  toxicity,  and  a  further  15  drugs  showing 
increased cytotoxicity in cells with P-glycoprotein. 
Analysis of these compounds has led to the formula-
tion of structure activity relationships linking mecha-
nism of action with metal chelation, and shows that 
p-glycoprotein is not the only target of compounds 
that are effective in MDR cells.5
However, there are a few known limitations to text 
mining. Associations are based on the use of constant 
terminology for a drug or gene, whereas this may 
not be the case for example, where drug names are 
changed by companies. Also there is restricted access 
to full text journals and also restriction to abstract Cancer drug discovery and clinical trial design
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Table 1. A selection of databases with direct application to cancer drug and target molecule discovery.
Database/resource used Mining tool used Reference/website notes
Clinical trials.gov Text http://clinicaltrials.gov/ A list of clinical trials taking 
or taken place: currently 
80,055 trials with locations in 
170 countries
Pubmed Text http://www.ncbi.nlm.nih.
gov/pubmed
Public access but no 
abstract publications 
available on this database
Web of knowledge Text http://wok.mimas.ac.uk/ Abstract publications + full 
papers available
oncomine Gene array data https://www.oncomine.org/
resource/login.html
Largest cancer specific 
microarray based database. 
(48,000,000 gene 
expression measurements 
from over 4700 microarray 
experiments
CGAP database Gene array data www.ncbi.nlm.nih.gov/ncicgap. Contains cancer specific 
cDnA libraries, clones, and 
sequence data in addition 
to microarray data. Public 
access
Gene expression atlas Gene array data http://www.geneatlas.org Uses gene expression data 
from tissue samples
Genemap Gene array data http://robotics.stanford.
edu/∼erans/cancer/
run by Stanford university: 
1975 published microarrays 
spanning 22 tumor types
Pathway studio Gene array data and text http://www.ariadnegenomics.
com/products/pathway-studio/
Private software program 
integrating gene array and 
text mining analyses to 
identify pathways of action 
for genes/drugs
open proteomics 
database
mass spectrometry data http://bioinformatics.icmb.
utexas.edu/oPD/
Public database for storing 
and disseminating mass 
spectrometry based 
proteomics data. The 
database currently contains 
roughly 3,000,000 spectra 
representing experiments 
from 5 different organisms
emBL proteomic 
database (Pride 
database)
mass spectrometry data http://www.ebi.ac.uk/pride/ PrIDe currently contains: 
9,964 experiments, 
2,564,320 proteins, 
12,015,539 peptides 
1,753,906 unique Peptides 
53,348,019 Spectra
nCI clinical proteomics 
program
Seldi-Tof data http://home.ccr.cancer.gov/
ncifdaproteomics/ppatterns.
asp
restricted at present to 
seldi-tof data sets from 
ovarian and pancreatic 
cancer data sets. Just data 
sets and not a database as 
such at presentGalustian and Dalgleish
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publications and some chemical and physical science 
journals in databases such as pubmed so that data 
associations need to be retrieved from a more limited 
source of overall citations. Text mining may therefore 
be better utilized by combining it with other data 
mining  tools  such  as  microarray  database  mining. 
This  uses  microarray  gene  data  from  experiments 
which have analysed genomes or sets of genes of 
particular cells or tissues.6 This allows the discovery 
of drug sensitive and disease specific genes which can 
be used to identify targets for cancer therapy. Such 
analyses yield vast amounts of gene data as even a 
whole genome can be available on a chip. When text 
mining and microarray data mining are combined, 
powerful analyses of data can be applied to decipher 
cancer  therapy  targets.  For  example,  Ho  and  col-
leagues have identified a set of 64 genes that are spe-
cifically expressed in endothelial cells compared with 
non endothelial cell types from combined text mining 
and microarray analyses.7 There are also caveats that 
can  be  applied  to  microarray  mining.8  Microarray 
analysis results in a vast amount of gene data from a 
dataset of samples that is normally at least 100 fold 
less than the gene data generated. There is also the 
problem of noise where artifactual expression may be 
seen with platforms that are not stringent enough to 
filter outlier data, and the requirement for repeat array 
analysis which sometimes shows variance in the fold 
change produced in single genes.9 This type of analy-
sis always requires a post test to confirm the gene 
changes observed, either quantitative pcr or western 
blotting of the associated proteins. Microarray gene 
data can be complemented by proteomic data analy-
sis such as mass spectrometric analysis, SELDI-TOF 
(Surface-enhanced  laser  desorption/ionization-time 
of  flight)  and  bio-plex  technologies  which  allow 
analysis  of  very  large  numbers  of  proteins  on  an 
array format and combined analyses of proteins and 
genes (often referred to as pathway analyses). These 
techniques  both  complement  and  strengthen  the 
observations seen with the genes alone. For example, 
this approach has been used to determine biomark-
ers which can give a very early prognosis of ovarian 
cancer.10 Such an approach has also recently helped 
to lead to discovery of biomarkers which can predict 
a  favourable  response  to  prostate  cancer  vaccines 
(Bodman-Smith et al, paper in preparation).
The power of data mining has now been harnessed 
by a growing industry specialising in the production 
of databases which can utilise text or gene or protein 
data. A selection of databases with direct application 
to cancer drug or target molecule discovery are pre-
sented in Table 1.
The tools that these databases provide for both the 
drug industry and academia can maximise the min-
ing process compared to manual mining techniques. 
Whereas data mining has not yet resulted in blockbuster 
discovery on its own merit, the use of this technology 
harnessed with the power of dedicated databases and 
bench top research, has already contributed to deci-
phering mechanisms of action of genes and drugs and 
should allow a much more rapid progress toward dis-
covery of effective cancer therapies in the future.
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